Harold Bernstein Sells 16,142 Maze Therapeutics Shares at $27.61 Each

Harold Bernstein, President of Research and Development (R&D) and Chief Medical Officer (CMO) of Maze Therapeutics, Inc. (MAZE), sold 16,142 shares of the company for a total of $445,620 at a per-share price of $27.61 on August 15, 2026.

Who is Harold Bernstein and What is His Real Role at Maze Therapeutics

Harold Bernstein serves as the President of R&D and CMO at Maze Therapeutics. In this role, he is responsible for the strategic direction and implementation of the company's research and development efforts, as well as overseeing the medical aspects related to the company's products and services. As a member of senior management, Bernstein has access to material information regarding the company's financial health, ongoing projects, and future prospects.

Bernstein's role at Maze Therapeutics entails a deep understanding of the company's internal processes, including product developments, clinical trials, and commercialization strategies. This position also empowers him to influence key decisions regarding the company's future direction and its investments in various health-related domains.

As President of R&D and CMO, Bernstein plays a critical role in identifying growth opportunities for Maze Therapeutics, as well as in managing potential risks associated with research and development projects. His position within senior management provides him with a unique perspective on the company's strengths and weaknesses, as well as on market trends and stakeholder expectations.

Transaction Details: 16,142 Shares at $27.61 Each

The transaction involved the sale of 16,142 Maze Therapeutics shares at a per-share price of $27.61. It is important to note that this per-share price and the total transaction value ($445,620) are two distinct figures reflecting, respectively, the cost of each share sold and the total amount generated from the transaction.

The transaction date, August 15, 2026, is also a key detail as it indicates the exact timing of the sale. This information may be relevant for investors tracking insider movements and seeking to understand potential performance trends or indicators related to the company.

Why Insiders Sell Their Shares – Possible Reasons

There are several reasons why insiders, such as Harold Bernstein, might choose to sell their shares. Portfolio diversification is one such reason, as insiders may seek to spread their investments to mitigate risks. Tax planning could also be a potential motive, as the sale of shares may be executed to meet tax obligations or to take advantage of favorable tax conditions.

Personal liquidity needs could also drive insiders to sell their shares. This may include covering personal expenses, funding projects or external investments, or simply having liquid cash on hand for unforeseen expenses. It is also possible that insiders sell their shares due to a perceived bearish signal, anticipating a potential decline in the stock price in the future.

However, it is important to qualify these reasons without drawing definitive conclusions about the stock's direction. Insiders may sell for reasons unrelated to company performance or outlook. Therefore, individual investors should consider these transactions within the broader context of market trends and company fundamentals.